Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vofatamab - Rainier Therapeutics

Next Previous
Drug Profile

Vofatamab - Rainier Therapeutics

Alternative Names: Anti FGR3; B 701; MFGR 1877A

Latest Information Update: 24 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioClin Therapeutics
  • Developer Rainier Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Urogenital cancer
  • No development reported Achondroplasia; Multiple myeloma; Solid tumours

Most Recent Events

  • 01 Dec 2019 Rainier Therapeutics terminates the phase Ib/II FIERCE-22 trial in Urogenital cancer (Late-stage disease, Monotherapy, Second-line therapy or greater, Metastatic disease, Monotherapy) in the US, Belgium, Denmark, Hungary, France, Germany, Italy, South Korea, Moldova, Netherlands, Poland, Russia, Serbia, Spain, Sweden, Turkey and Ukraine (IV), since the programme was put on hold by the sponsor (NCT03123055)
  • 18 Nov 2019 Rainier Therapeutics terminates the phase I/IIb FIERCE-21 trial in Urogenital cancer (Late-stage disease, Combination therapy, Second-line therapy or greater, Metastatic disease, Monotherapy) in the Italy, South Korea, Spain, Sweden, Turkey, Czech Republic, Taiwan, United Kingdom and USA (IV) since the programme was put on hold by the sponsor (NCT02401542)
  • 27 Sep 2019 Updated interim efficacy and adverse events data from the FIERCE-22 phase Ib/II trial in Bladder Cancer presented at the 44th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top